Shire buys Premacure AB
Expanding its rare disease drug pipeline, Shire PLC has acquired closely held Swedish neonatology biotech Premacure AB for an undisclosed up-front payment and earn-outs based on development and commercialization of its Phase II protein replacement therapy for retinopathy of prematurity (ROP).
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.